Establishment of lymphangioma model and a study on the promoting effect of murine melanoma cell B16-F1 on the lymphangiogenesis in vitro

Abstract

To establish an animal model of benign lymphangiomas of C57BL/6 mouse in vitro and to observe the effect of mouse ascites melanoma cell B16-F1 on the lymphangiogenesis, 16 C57BL/6 mice aged 8 weeks were given two intraperitoneal injections of incomplete Freund’s adjuvant at a 15-day interval. The induced neoplasms were studied histopathologically and thhe neoplasms specimens were immunohistochemically examined for the expressions of VEGF-C (vascular endothelial growth factor-C) and Flt-4 (VEGFR-3, vascular endothelial growth factor receptor-3). The neoplasms were harvested and embedded in fibrin gel for culture in conditioned medium of B16-F1 cells in vitro and observed under inverted microscope. Our results showed that white solid tumor masses developed in peritoneal cavity after the induction. The tumors were confirmed to be lymphangioma by gross and histological examination. The tumor cells expressed both VEGF-C and Flt-4. Lymphatic capillaries coming from lymphangioma specimen grew into the gel and the conditioned medium of B16-F1 cells was found to be able to promote the growth of the vessels. It is concluded that intraperitoneal injection of incomplete Freund’s adjuvant is a good method for inducing benign lymphangiomas in mouse and B16-F1 cells can promote lymphangiogenesis.

Keywords

melanoma / lymphangiogenesis / lymphatic metastasis

References

[1] PartanenT. A., PaavonenK.. Lymphatic versus blood vascular endothelial growth factors and receptors in humans. Microsc Res Tech, 2001, 55: 108-121

[2] JacquemierJ., Mathoulin-PotierM. P., ValtolaR., et al.. Prognosis of breast-carcinoma lymphagenesis evaluated by immunohistochemical investigation of vascular-growth-factor receptor 3. Int J Cancer, 2000, 89: 69-73

[3] FlemingS. T., RastogiA., DemtrienkoA., et al.. A comprehensive prognosic index to predict survival based on multiple comborbidities: a focus in breast cancer. Med Care, 1999, 37(6): 601-604

[4] SkobeM., HawighorstT., JacksonD. G., et al.. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nature Med, 2001, 7(2): 192-198

[5] KarpanenT., EgebladN., KarkkainenM. J., et al.. Vascular endothelia growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res, 2001, 61(5): 1786-1790

[6] PeppersM. S.. Lymphangiogenesis and tumor metastasis: myth or reality. Clin Cancer Res, 2001, 7(3): 462-468

[7] WiltingJ., NeeffH., ChristB.. Embryonic lymphangiogenesis. Cell Tissue Res, 1999, 297(1): 1-11

[8] JussilaL., AlittaloK.. Vascular growth factors and lymphangiogenesis. Physiol Rev, 2002, 82(3): 673-700

[9] van TrappenP. O., PepperM. S.. Lymphatic dissemination of tumor cells and the formation of micrometastases. Lancet Oncol, 2002, 3(1): 44-52

[10] StimpflM., TongD., FaschingB., et al.. Vascular endothelial growth factor splice variants and their prognostic value in breast and ovarian cancer. Clin Cancer Res, 2002, 8(7): 2253-2259

[11] NakamuraM., AbeY., TokunagaT.. Pathological significance of vascular endothelial growth factor A isoform expression in human cancer. Pathol Int, 2002, 52(5–6): 331-339